Menu
Search
|

Menu

Close
X

Arcturus Therapeutics Ltd ARCT.OQ (NASDAQ Stock Exchange Global Market)

5.40 USD
-0.01 (-0.18%)
As of 4:00 PM EDT
chart
Previous Close 5.41
Open 5.40
Volume 1,881
3m Avg Volume 8,950
Today’s High 5.46
Today’s Low 5.40
52 Week High 10.00
52 Week Low 4.11
Shares Outstanding (mil) 10.70
Market Capitalization (mil) 57.49
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
8
FY17
24
FY16
20
EPS (USD)
FY18
-2.065
FY17
-4.839
FY16
3.675
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
2.71
8.99
Price to Book (MRQ)
vs sector
4.07
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.49
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-70.90
12.11
Return on Equity (TTM)
vs sector
-83.56
13.22

EXECUTIVE LEADERSHIP

Peter Farrell
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Joseph Payne
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Andrew Sassine
Chief Financial Officer, Director, Since 2019
Salary: --
Bonus: --
Pad Chivukula
Chief Operating Officer, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
Kevin Skol
Senior Vice President - Business Development & Alliance Management, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10628 Science Center Dr Ste 200
SAN DIEGO   CA   92121-1128

Phone: +1858.9002660

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is a development-stage biopharmaceutical company. The Company is developing portfolio of ribonucleic acid (RNA) therapeutics for treatment of diseases. Its Messenger RNA can be used as protein replacement therapy to treat diseases caused by a lack of protein such as cystic fibrosis. Its technology includes a lipid-mediated delivery system called Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR). The Company's second technology is an oligonucleotide chemistry technology called Unlocked Nucleomonomer Agent (UNA). The Company's platform includes LUNAR-HBV, LUNAR-NASH and LUNAR-GSD3. LUNAR-HBV is a nucleic acid medicine. LUNAR-NASH Nonalcoholic steatohepatitis develops RNA-based therapeutic candidates to treat NASH. LUNAR-GSD3 Glycogen Storage Disease type III is a genetic disease. It develops mRNA medicines to replace the defective Acute Granulocytic Leukemia (AGL) gene product and allow cells to breakdown glycogen.

SPONSORED STORIES